FDA OKs 23andMe Test

The US Food and Drug Administration will allow the personal genomics company to resume a disease-risk analysis.

By | February 20, 2015

WIKIMEDIA, MAGGIE BARTLETT, NHGRIPersonal genomics testing firm 23andMe is easing back into health-prediction service after the US Food and Drug Administration (FDA) yesterday (February 19) gave its blessing for the company to market a test that would predict the risk of a rare disease called Bloom Syndrome. The FDA had put a stop to all of 23andMe’s health-prediction services in 2013 over concerns that the firm was overstepping its scientific authority.

“While this authorization is for a single carrier status test only, we are committed to providing US customers with health information once more tests have been through this process and we have a more comprehensive product offering,” CEO Anne Wojcicki wrote on the 23andMe blog.

As Forbes pointed out, “[t]he major news, however, is that the [FDA] also took this opportunity to announce that home-use genetic testing for other carrier genes will be exempt from premarketing approval, designating such tests as Class II diagnostics.”

According to the agency’s press release, “[t]his action creates the least burdensome regulatory path for autosomal recessive carrier screening tests with similar uses to enter the market.” 

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Man Receives First In Vivo Gene-Editing Therapy
  2. Researchers Build a Cancer Immunotherapy Without Immune Cells
  3. Long-term Study Finds That the Pesticide Glyphosate Does Not Cause Cancer
  4. Research Links Gut Health to Neurodegeneration
    The Nutshell Research Links Gut Health to Neurodegeneration

    Rodent studies presented at the Society for Neuroscience meeting this week tie pathologies in the gastrointestinal tract or microbiome composition with Parkinson’s and Alzheimer’s diseases.

RayBiotech